Literature DB >> 29241763

Eltrombopag reduces clinically relevant thrombocytopenic events in higher risk MDS and AML.

Aditi Shastri1, Amit K Verma2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29241763     DOI： 10.1016/S2352-3026(17)30229-6

Source DB:  PubMed          Journal:  Lancet Haematol        ISSN： 2352-3026            Impact factor:   18.959


× No keyword cloud information.
  2 in total

Review 1.  Myelodysplastic syndromes current treatment algorithm 2018.

Authors:  David P Steensma
Journal:  Blood Cancer J       Date:  2018-05-24       Impact factor: 11.037

2.  Safety and Efficacy of Eltrombopag and Romiplostim in Myelodysplastic Syndromes: A Systematic Review and Meta-Analysis.

Authors:  Fanqiao Meng; Xiuqiong Chen; Shunjie Yu; Xiaotong Ren; Zhaoyun Liu; Rong Fu; Lijuan Li
Journal:  Front Oncol       Date:  2020-11-26       Impact factor: 6.244
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.